Skip to main content
. 2020 Sep 14;137(6):751–762. doi: 10.1182/blood.2020007732

Figure 3.

Figure 3.

Relation between CRS and antileukemic activity. (A) Relation between BM blast change and number of days patient experienced CRS during cycle 1. (B) Relation between BM blast change and number of CRS events during cycle 1. (C) Relation between BM blast change and CRS severity (mean grade for all events per patient) during cycle 1. Simple regression is shown as red line; dotted lines depict 95% CI.